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Copenhagen, Denmark; and j Division Woman & Baby, University Medical Center Utrecht, Utrecht, the NetherlandsObjective: To evaluate the dose–response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian
response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the inﬂuence of initial
antim€ullerian hormone (AMH) concentrations.
Design: Randomized, controlled, assessor-blinded, AMH-stratiﬁed (low: 5.0–14.9 pmol/L [0.7–<2.1 ng/mL]; high: 15.0–44.9 pmol/L
[2.1–6.3 ng/mL]) trial.
Setting: Seven infertility centers in four countries.
Patient(s): Two hundred sixty-ﬁve women aged%37 years.
Intervention(s): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 mg of rhFSH, or 11 mg (150 IU) of follitropin alfa in
a GnRH antagonist cycle.
Main Outcome Measure(s): Number of oocytes retrieved.
Result(s): The number of oocytes retrieved increased in an rhFSH dose–dependent manner, from 5.2 3.3 oocytes with 5.2 mg/d to 12.2
 5.9 with 12.1 mg/d. The slopes of the rhFSH dose–response curves differed signiﬁcantly between the two AMH strata, demonstrating
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONthat a 10% increase in dose resulted in 0.5 (95% conﬁdence interval 0.2–0.7) and 1.0 (95% conﬁdence interval 0.7–1.3) more oocytes in
the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased signiﬁcantly with increasing
rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by
AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH
stratum.
Conclusion(s): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. TheUse your smartphoneavailability of blastocysts is less inﬂuenced by the rhFSH dose and AMH level.
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scanner” in your smartphone’s app store or app marketplace.T he purpose of controlled ovarian stimulation (COS)with gonadotropins for IVF/intracytoplasmic sperm in-jection (ICSI) is to obtain an adequate number of
competent oocytes with the minimum risks for the woman
(1). The magnitude of the ovarian response and the number
of embryos/blastocysts available for transfer is generally
considered to be a function of the gonadotropin dose (2),
the type of stimulation protocol (3–6), and the patient's
proﬁle (7–9).
Individual variability in ovarian response to a given dose
of gonadotropins is well recognized, and signiﬁcant efforts
have been made to identify clinical parameters that can pre-
dict ovarian response, as well as lead to improved efﬁcacy and
safety outcomes (10–13). The use of biomarkers of the
functional ovarian reserve (14) in combination with
prospectively designed gonadotropin dose–response studies
should deﬁne more patient-tailored dosing regimens that
fulﬁll both the clinical efﬁcacy and safety objectives for
COS. The initial serum concentration of antim€ullerian hor-
mone (AMH) is increasingly being recognized as the preferred
biomarker of ovarian response to COS compared with patient
age, day-3 FSH, inhibin B, and E2 (15), and to be as good as
antral follicle count (AFC) assessed by ultrasound (16, 17),
but with less intra- and intercycle variation than AFC (18).
Moreover, AMH assessments can be applied to all IVF
clinics, independent of observers' bias.
The present investigation evaluated the dose–response
relationship of a novel recombinant human FSH (rhFSH;
FE 999049) with respect to ovarian response in patients un-
dergoing COS for IVF/ICSI and studied the inﬂuence of
initial AMH concentrations on the dose–response curve. Re-
combinant human FSH is expressed from a cell line of hu-
man fetal retinal origin (PER.C6) with an amino acid
sequence identical to the native human FSH sequence and
existing recombinant FSH preparations derived from Chi-
nese hamster ovary (CHO) cell lines (i.e., follitropin alfa
and beta). The human cell line was chosen to resemble the
glycosylation proﬁle of native human FSH. In fact, the sialic
acid content of rhFSH is different and more complex, with
both a2,3 and a2,6 sialylation compared with the CHO-
derived FSH products, which only contain a2,3 sialylation
(19). The composition of the carbohydrate moieties can1634modulate the in vivo activity of FSH by impacting its clear-
ance and, potentially, by the binding properties to the FSH
receptor. Previous studies in healthy women showed that
administration of identical bioactive doses (international
units [IU] based on the Steelman-Pohley in vivo rat assay)
of rhFSH and follitropin alfa resulted in slower clearance
for rhFSH and signiﬁcantly higher pharmacodynamic
responses with rhFSH in terms of serum E2 and inhibin B,
as well as more follicles (20). Because the translation of
biological activity in IU from a rat assay to humans is not
the same for rhFSH and CHO-derived FSH products, a
dose–response characterization of the novel rhFSH was
needed in patients undergoing COS for IVF/ICSI treatment.
MATERIALS AND METHODS
This was a randomized, controlled, open-labeled, parallel-
group phase 2 trial conducted at seven centers in four
countries (Belgium, Czech Republic, Denmark, and Spain)
from September 2011 through May 2013. The trial was
assessor-blinded, and all investigators, embryologists, central
laboratory personnel, and sponsor staff involved in analyzing
and interpreting data were kept blinded to treatment
allocation throughout the trial. The study was performed in
accordance with the Declaration of Helsinki, the International
Conference on Harmonization Guidelines for Good Clinical
Practice, and local regulatory requirements. The study proto-
col was approved by the local regulatory authorities and the
independent ethics committees covering all participating
centers. All patients provided written, informed consent.Trial Population
Women diagnosed with tubal infertility, unexplained infer-
tility, infertility related to endometriosis stage I/II, or with
partners diagnosed with male factor infertility were eligible
for the trial. Additional main inclusion criteria were as fol-
lows: age 18–37 years; body mass index 18.5–32.0 kg/m2;
infertility for at least 1 year before randomization; regular
menstrual cycles of 24–35 days, presumed to be ovulatory;
hysterosalpingography, hysteroscopy, or transvaginal ultra-
sound documenting a uterus consistent with expected normal
function; transvaginal ultrasound documenting presenceVOL. 102 NO. 6 / DECEMBER 2014
Fertility and Sterility®and adequate visualization of both ovaries, without evidence
of signiﬁcant abnormality; early follicular phase FSH
serum concentration of 1–12 IU/L and total antral follicle
(diameter 2–10 mm) count R6 and %25 for both ovaries
combined; serum AMH concentration of 5.0–44.9 pmol/L
(0.7–6.3 ng/mL); willing to accept transfer of one blastocyst
in the fresh cycle; and willing to accept transfer of one blas-
tocyst in frozen embryo replacement cycles initiated within
6 months after randomization. The main exclusion criteria
were as follows: known polycystic ovary syndrome associated
with anovulation; known endometriosis stage III–IV; three or
more COS cycles for IVF/ICSI; poor ovarian response in a pre-
vious COS cycle using an average daily FSH dose R150 IU,
deﬁned as development of fewer than four follicles
R15 mm or cycle cancellation due to limited follicular
response; excessive ovarian response in a previous COS cycle
using an average daily FSH dose <225 IU, deﬁned as >25
oocytes retrieved or cycle cancellation due to excessive
ovarian response, including risk of ovarian hyperstimulation
syndrome (OHSS); severe OHSS in a previous COS cycle; his-
tory of recurrent miscarriage; current or past (up to 1 year
before randomization) abuse of alcohol or drugs; and intake
of more than 14 units of alcohol per week during the past
month or smoking more than 10 cigarettes per day within
3 months before randomization.Treatment Regimen
On day 2–3 of the menstrual cycle, patients were randomly
assigned, in a 1:1:1:1:1:1 ratio, to receive ﬁxed daily SC injec-
tions of either 5.2 mg, 6.9 mg, 8.6 mg, 10.3 mg, or 12.1 mg of
rhFSH (FE 999049; Ferring Pharmaceuticals), or 11 mg (150
IU) of follitropin alfa (Gonal-F ﬁlled by mass; Merck Serono).
The rhFSH dose is expressed in micrograms because the deter-
mination of potency by the pharmacopoeial rat bioassay
(Steelman-Pohley in vivo bioassay, IU) does not fully reﬂect
the response of this rFSH preparation from a human cell
line when administered to humans (20). Follitropin alfa was
included as the reference arm for validation purposes of the
ovarian response. Randomization was stratiﬁed according
to the patients' serum concentration of AMH at the screening
visit (low stratum: 5.0–14.9 pmol/L [0.7–<2.1 ng/mL]; high
stratum: 15.0–44.9 pmol/L [2.1–6.3 ng/mL]) and by trial site
using a block size of six. An independent statistician in the
Department of Biometrics at Ferring Pharmaceuticals gener-
ated the randomization list using SAS version 9.2 (SAS Insti-
tute). Randomization was performed centrally through the
electronic Case Report Form system by assigning the lowest
randomization number available within stratum.
On stimulation day 6, a GnRH antagonist (ganirelix ace-
tate; Ganirelix Acetate Injection/Orgalutran, Merck/MSD)
was initiated at a daily dose of 0.25 mg and continued
throughout the stimulation period. When three or more folli-
cles with a diameter R17 mm were observed, triggering of
ﬁnal follicular maturation was done with 250 mg recombinant
hCG (choriogonadotropin alfa; Ovidrel/Ovitrelle, EMD
Serono/Merck Serono) if there were <25 follicles R12 mm,
or with 0.2 mg GnRH agonist (triptorelin acetate; Decapeptyl,
Ferring Pharmaceuticals) if there were 25–35 folliclesVOL. 102 NO. 6 / DECEMBER 2014R12 mm. In case of >35 follicles R12 mm, the cycle was
to be cancelled; coasting was not allowed. In case of fewer
than three follicles R10 mm observed on stimulation day
10, the cycle could be cancelled.
Oocyte retrieval took place 36  2 hours after triggering
of ﬁnal follicular maturation, and the oocytes could be insem-
inated by IVF or ICSI. For patients who underwent triggering
with hCG, a single blastocyst-stage embryo of the best quality
according to the criteria of Gardner and Schoolcraft (21) was
transferred on day 5 after oocyte retrieval while surplus blas-
tocysts could be cryopreserved. For patients who underwent
triggering with GnRH agonist, no transfer took place in the
fresh cycle, and the blastocysts were instead cryopreserved.
Vaginal progesterone tablets (Endometrin/Lutinus, Ferring
Pharmaceuticals) 100 mg three times daily were provided
for luteal-phase support from the day after oocyte retrieval
until the clinical pregnancy visit. Patients with cryopreserved
blastocysts could undergo cryopreserved replacement cycles,
initiated within 6 months of randomization, with compulsory
single-blastocyst transfer in a natural cycle.Trial Endpoints and Trial Assessments
The primary endpoint was the number of oocytes retrieved.
The secondary endpoints included duration of stimulation,
fertilization, blastocyst number and quality, pregnancy, live
birth, and OHSS. The serum concentration of AMH (1 ng/
mL ¼ 7.143 pmol/L) at screening was assessed by a central
laboratory using the Beckman Coulter Gen 2 ELISA assay,
after being stored at ambient temperature between 1 and
5 days to avoid possible complement interference. Circulating
levels of FSH were assessed by a central laboratory using an
electrochemiluminescence immunoassay. A serum b-hCG
test was performed 13–15 days after transfer. Clinical preg-
nancy, deﬁned as at least one intrauterine gestational sac
with fetal heart beat, was conﬁrmed by ultrasound 5-6 weeks
after transfer. All pregnancies in fresh and cryopreserved cy-
cles were followed until live birth.Sample Size and Statistical Analysis
The trial was dimensioned to have 90% power of demon-
strating a dose–response relationship of rhFSH with respect
to oocytes retrieved at the two-sided 5% signiﬁcance level.
The power calculation assumed an increase in number of
oocytes retrieved ofR3.5 when doubling the dose and a stan-
dard deviation of 5.6, yielding 200 subjects equally distrib-
uted across the ﬁve rhFSH groups and thus a total of 240
subjects for the six treatment groups, including the reference
arm.
All summaries and analyses are based on the intention-
to-treat population grouped according to treatment received.
The primary endpoint was modeled using analysis of covari-
ance (ANCOVA), with center and AMH stratum as factors and
log(dose) as covariate including an interaction between AMH
stratum and log(dose). Six rhFSH-treated subjects who
cancelled the cycle because of poor response were included
in the dose–response modeling as having one oocyte
retrieved. One subject who discontinued for personal reasons1635
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ness was veriﬁed by repeating the analysis for observed data.
The analysis was repeated within each AMH stratum. Dose–
response for continuous variables was evaluated by ANCOVA
using a similar model structure as for the primary endpoint.
Dose–response for binary endpoints was evaluated by logistic
regression including AMH stratum and log(dose) in themodel.
Pregnancy and live birth rates were compared across rhFSH
treatment groups and between AMH strata using c2 tests.
All statistical analyses were performed in SAS version 9.2.
The reference arm (follitropin alfa, 11 mg) was included for
external validity, and no statistical comparisons were
contemplated.RESULTS
Trial Population
Details of the patients participating in the study are shown
in Supplemental Figure 1 (available online). Of the 334 pa-
tients who were screened, 265 eligible patients were ran-
domized, with a distribution of 56% (n ¼ 148) and 44% (n
¼ 117) in the high and low AMH stratum, respectively.
The majority of the subjects where white (259 of 265) and
not Hispanic or Latino (262 of 265). The distribution of
initial AMH values in the trial population is shown in
Supplemental Figure 2. A total of 222 patients received
one of the ﬁve doses of rhFSH, and 43 patients received
11 mg follitropin alfa. Demographics and baseline character-
istics were not signiﬁcantly different between the treatment
groups (Supplemental Table 1), whereas signiﬁcantly higher
mean AFC values (P< .001) and lower median basal FSH
values (P< .001) were observed for patients with high
AMH compared with low AMH.COS and Oocyte Retrieval
The mean duration of stimulation decreased signiﬁcantly
(P< .001) with increasing doses of rhFSH; however, at each
dose level, the duration of stimulation was similar between
the AMH strata (Table 1). Cycle cancellation before oocyte
retrieval occurred in seven patients; one because of personal
reasons and six because of poor response, of whom ﬁve
were in the low AMH stratum (Supplemental Fig. 1).
A total of 258 women (97%) underwent oocyte retrieval,
of whom 256 had triggering of ﬁnal follicular maturation
with hCG, and two patients in the high AMH stratum had
excessive ovarian response leading to triggering with GnRH
agonist (Supplemental Fig. 1). Among the women treated
with rhFSH, the mean number (SD) of oocytes retrieved
increased from 5.2  3.3 in the 5.2 mg group to 12.2  5.9
in the 12.1 mg group, and was 10.4 5.2 in the 11 mg follitro-
pin alfa group (Table 1). A statistically signiﬁcant (P< .001)
dose–response relationship with respect to number of oocytes
retrieved was established for rhFSH (Fig. 1A). This relation-
ship remained signiﬁcant (P< .001) within both AMH strata,
whereas the slopes of the dose–response curves differed
signiﬁcantly between the two strata (P¼ .025). The dose–
response model predicted that a 10% increase in rhFSH dose
would result in an increase of 0.5 oocyte (95% conﬁdence1636interval 0.2–0.7) in the low AMH stratum and 1.0 oocyte
(95% conﬁdence interval 0.7–1.3) in the high AMH stratum.
A responder analysis of the primary endpoint showed that
the proportion of patients with an adequate ovarian response,
deﬁned as 8–14 oocytes retrieved, was most frequent in the
8.6 mg (54%) and 12.1 mg groups (60%) in the high and low
AMH stratum, respectively (Fig. 1B and C).Fertilization Rate and Blastocyst Availability
The fertilization rate, as well as the probability that an
oocyte developed to a blastocyst, decreased signiﬁcantly
with increasing rhFSH doses (P< .001) (Fig. 2, Table 1).
The mean number of blastocysts and blastocysts of good
quality was in the range of 2.3–3.2 and 0.9–1.4, respectively,
across the rhFSH groups, with no signiﬁcant linear dose–
response relationship, either overall (Table 1) or within
AMH strata (Fig. 3). In the high AMH stratum, there were
no statistically signiﬁcant differences among groups in the
number of total or good-quality blastocysts. Nevertheless,
in the low AMH stratum, the number of blastocysts and
good-quality blastocysts were signiﬁcantly (P< .05) higher
in the 12.1 mg group compared with the other rhFSH dose
groups combined.
In the ICSI cycles (81% of all cycles) in which nuclear
maturation was determined before insemination, the ﬁnd-
ings were similar to those in the overall population, with
a signiﬁcant dose–response effect of rhFSH for number of
oocytes retrieved (P< .001) and metaphase II oocytes
(P< .001), but not for the number of blastocysts and
good-quality blastocysts (Supplemental Fig. 3). The number
of metaphase I oocytes increased signiﬁcantly (P< .001)
with rhFSH dose, from 0.3  0.5 (5.6 mg) to 1.0  1.2
(12.1 mg); and the number of germinal vesicle oocytes
also increased signiﬁcantly (P< .001) with rhFSH dose,
from 0.5  0.8 (5.6 mg) to 1.8  2.6 (12.1 mg)
(Supplemental Table 2). The probability that a metaphase
II oocyte developed to a blastocyst decreased signiﬁcantly
with increasing rhFSH doses overall (P< .001) and in the
high AMH stratum (P< .001), but not in the low AMH
stratum (Supplemental Fig. 3).Treatment Outcome
In the fresh cycle, no statistically signiﬁcant relationships
between the rhFSH dose and positive b-hCG, clinical preg-
nancy, and live birth rates were observed (Table 1). The cu-
mulative live birth rate (the fresh blastocyst transfer cycle
plus subsequent frozen–thawed blastocyst transfer cycles)
was numerically higher in the high AMH stratum (46% vs.
36%, P¼ .133); most likely as a consequence of the signiﬁ-
cantly higher number of blastocysts, total (3.2  2.7 vs. 2.2
 1.6, P¼ .017) and of good-quality (1.4  1.6 vs. 0.9  1.1,
P¼ .028), in the high AMH stratum compared with the low
AMH stratum. However, it should be noted that the trial
was not powered to detect differences in pregnancy and
live birth rates between the treatment groups. A total of
ﬁve moderate/severe OHSS were reported, and all in
the high AMH stratum: two early OHSS in patients exposedVOL. 102 NO. 6 / DECEMBER 2014
TABLE 1
Stimulation and outcome variables of the patients, according to treatment group and AMH stratum.
Variable
rhFSH
P valuea
Follitropin alfa
11 mg (n[ 43)
5.2 mg
(n[ 42)
6.9 mg
(n[ 45)
8.6 mg
(n[ 44)
10.3 mg
(n[ 44)
12.1 mg
(n[ 47)
Duration of stimulation, d
All patients 9.6  2.2 9.0  2.0 8.4  1.6 7.9  1.4 8.1  1.8 < .001 8.6  1.6
Low AMH stratumb 9.2  2.3 8.6  1.8 8.5  1.4 7.9  1.5 7.9  2.4 .009 8.6  1.4
High AMH stratumc 10.0  2.2 9.3  2.1 8.3  1.9 7.9  1.3 8.3  1.2 < .001 8.6  1.8
Oocytes retrieved, n
All patients 5.2  3.3 7.9  5.9 9.2  4.6 10.5  7.0 12.2  5.9 < .001 10.4  5.2
Low AMH stratum 4.5  2.2 6.3  4.9 7.4  3.8 6.9  3.6 9.4  4.9 < .001 7.8  3.4
High AMH stratum 5.9  3.9 9.1  6.4 10.6  4.8 13.6  7.8 14.4  5.8 < .001 12.4  5.4
Fertilization rate, %
All patients 66  27 65  19 53  23 58  28 56  20 < .001 62  23
Low AMH stratum 71  20 66  18 58  27 61  28 57  21 .005 63  21
High AMH stratum 62  31 64  20 49  18 56  28 56  20 .006 61  25
Blastocysts, n
All patients 2.3  1.7 3.1  2.7 2.7  2.0 2.8  2.8 3.2  2.2 .092 3.5  2.5
Low AMH stratum 2.2  1.3 2.4  1.4 2.3  1.5 2.0  1.6 3.1  2.0* .266 3.0  2.2
High AMH stratum 2.3  1.9 3.6  3.3 3.1  2.4 3.5  3.4 3.3  2.4 .188 3.9  2.7
Blastocysts/oocytes, %
All patients 45  27 40  23 30  18 32  28 29  19 < .001 35  23
Low AMH stratum 50  28 44  25 33  20 34  30 36  21 .038 38  26
High AMH stratum 42  27 38  22 27  16 30  27 25  17 < .001 33  21
Good-quality blastocysts,d n
All patients 0.9  1.2 1.4  1.7 1.2  1.2 1.4  1.5 1.3  1.3 .178 1.6  1.6
Low AMH stratum 0.9  0.9 0.9  1.1 0.6  0.9 1.0  1.1 1.5  1.5* .156 1.5  1.5
High AMH stratum 1.0  1.4 1.7  2.0 1.6  1.3 1.7  1.7 1.2  1.2 .487 1.7  1.8
Outcome in fresh cycle,e n (%)
Positive bhCG ratef
All patients 18/42 (43) 23/45 (51) 18/44 (41) 17/44 (39) 24/47 (51) .650 23/43 (53)
Low AMH stratum 8/19 (42) 8/19 (42) 9/20 (45) 9/20 (45) 9/21 (43) .999 10/18 (56)
High AMH stratum 10/23 (43) 15/26 (58) 9/24 (38) 8/24 (33) 15/26 (58) .271 13/25 (52)
Clinical pregnancy ratef
All patients 15/42 (36) 18/45 (40) 16/44 (36) 11/44 (25) 19/47 (40) .554 22/43 (51)
Low AMH stratum 6/19 (32) 6/19 (32) 7/20 (35) 5/20 (25) 7/21 (33) .970 10/18 (56)
High AMH stratum 9/23 (39) 12/26 (46) 9/24 (38) 6/24 (25) 12/26 (46) .538 12/25 (48)
Live birth ratef
All patients 15/42 (36) 17/45 (38) 16/44 (36) 11/44 (25) 18/47 (38) .670 20/43 (47)
Low AMH stratum 6/19 (32) 6/19 (32) 7/20 (35) 5/20 (25) 6/21 (29) .970 8/18 (44)
High AMH stratum 9/23 (39) 11/26 (42) 9/24 (38) 6/24 (25) 12/26 (46) .615 12/25 (48)
Cumulative live birth ratef,g
All patients 17/42 (40) 22/45 (49) 18/44 (41) 15/44 (34) 21/47 (45) .698 22/43 (51)
Low AMH stratum 7/19 (37) 8/19 (42) 7/20 (35) 6/20 (30) 8/21 (38) .955 8/18 (44)
High AMH stratum 10/23 (43) 14/26 (54) 11/24 (46) 9/24 (38) 13/26 (50) .816 14/25 (56)
Note: Plus-minus values are means  SD.
a P values reﬂect the dose–response relationship. For duration of stimulation, oocytes retrieved, number of blastocysts, and number of good-quality blastocysts the P values are based on ANCOVA
models with center and AMH stratum as factors and log(dose) as covariate. P values for fertilization rate and blastocyst-to-oocyte rate are based on logistic regression models with AMH stratum as
factor and log(dose) as covariate. P values for outcome variables are based on c2 tests.
b The low AMH stratum is a serum AMH concentration in the range from 5.0 to 14.9 pmol/L (0.7 to <2.1 ng/mL).
c The high AMH stratum is a serum AMH concentration in the range from 15.0 to 44.9 pmol/L (2.1 to 6.3 ng/mL).
d Blastocysts with a score of at least 3BB (i.e., expanding blastocysts with inner cell mass and trophectoderm gradings of A or B), according to the morphology grading system by Gardner and
Schoolcraft (21).
e Per started cycle.
f n/total n (%).
g Including patients with cryopreserved blastocyst transfer cycles initiated within 6 months after start of COS.
* P< .05 vs. the other dose groups.
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Fertility and Sterility®to the highest rhFSH dose groups (10.3 and 12.1 mg, respec-
tively), and three late OHSS (one in the 8.6 mg group and
two in the 12.1 mg group).DISCUSSION
The present study demonstrates for the ﬁrst time prospec-
tively a signiﬁcant AMH-dependent dose–response relation-
ship between exogenous FSH and number of oocytesVOL. 102 NO. 6 / DECEMBER 2014retrieved for IVF/ICSI. Different slopes of the dose–response
curves were established according to AMH levels. Across all
ﬁve tested rhFSH doses (5.2–12.1 mg), three to eight additional
oocytes were obtained in the women presenting with high
initial AMH concentrations compared with the low AMH
women when the same rhFSH doses were administered. Cycle
cancellation due to poor response was mainly clustered in the
low AMH stratum and distributed across the rhFSH dose
groups. Excessive response leading to changes in clinical1637
FIGURE 1
(A) Mean number of oocytes retrieved for patients in the ﬁve rhFSH
dose groups, overall and by AMH stratum. The vertical bars
represent standard errors. P values reﬂect the dose–response
relationship. (B, C) Relative proportions of patients with different
categories of number of oocytes retrieved by rhFSH dose group and
AMH stratum (B, high AMH; C, low AMH).
Arce. AMH and ovarian response to rhFSH. Fertil Steril 2014.
FIGURE 2
Mean rate of blastocysts to oocytes retrieved for patients in the ﬁve
rhFSH dose groups, (A) overall and by (B) AMH stratum. The
vertical bars represent standard errors. P values reﬂect the dose–
response relationship.
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONmanagement, such as administration of a GnRH agonist bolus
for triggering of ﬁnal follicular maturation, was observed
only in patients in the high AMH stratum. Additionally, the
ﬁve cases of moderate/severe OHSS occurred only in the
high AMH patient stratum and at the three highest doses of
rhFSH. These ﬁndings reinforce the concept that the choice
of an optimal gonadotropin dose for a given woman should
be guided by an ovarian reserve marker, such as the initial
serum level of AMH. Administration of a standard dose to
all patients without taking into consideration their functional
ovarian follicle reserve has been proven to cause major differ-
ences in degree of ovarian responses and safety issues, and1638furthermore, dose adjustments on stimulation day 6 to
compensate the initial responses have been reported as inef-
ﬁcient (22, 23). The present study included women up to
37 years of age. Antim€ullerian hormone has been shown to
be a better predictor of the ovarian response than age in
studies including women older than 37 years; see the review
by La Marca et al. (15). The follitropin alfa 11 mg (150 IU)
reference group had an ovarian response in line with
expectations in GnRH antagonist cycles (24) and provided
additional external validity to the dose–response curve for
rhFSH.
The present study also suggests an inverse relationship
between the rhFSH dose and fertilization and blastocyst-to-
oocyte rates, for women in both the high and low AMH stra-
tum. It can be speculated that the decrease in fertilization rate
observed with higher doses of rhFSH may partly be a conse-
quence of somewhat shorter stimulation periods affecting
the nuclear and cytoplasmic maturation. However, because
the duration of stimulation depends on the dose, the decrease
in fertilization rate could be a consequence of higher doses,VOL. 102 NO. 6 / DECEMBER 2014
FIGURE 3
Number of oocytes retrieved and blastocysts by rhFSH dose group
(A, high AHM; B, low AMH). The vertical bars represent standard
errors. P values reﬂect the dose–response relationship. * P<.05 vs.
other dose groups combined.
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Fertility and Sterility®either directly or indirectly. The increase in number of oocytes
retrieved obtained with higher rhFSH doses was not associ-
ated with a similar increase in the numbers of total blastocysts
or good-quality blastocysts available for fresh transfer or
cryopreservation. On the contrary, an apparent plateau
regarding the number of available blastocysts was achieved
with all rhFSH doses except the lowest in the high AMH
stratum, whereas in the low AMH stratum only the women
given the highest dose had equal numbers of blastocysts
available for transfer as the women in the high AMH stratum.
When administering a standard dose of gonadotropins in
women undergoing COS, a relatively good association
between the numbers of oocytes retrieved and blastocysts
available for transfer would be expected because the response
would be consistent with the ovarian reserve (i.e., the AMH
level). Nevertheless, in the present study the average AMH
level in all rhFSH dose groups was similar (Supplemental
Table 1) owing to the AMH stratiﬁcation at randomization,VOL. 102 NO. 6 / DECEMBER 2014and therefore facilitates the interpretation of the effect of
increasing gonadotropin doses and ovarian response poten-
tial on blastocyst availability.
High gonadotropin doses, or excessive ovarian response
to stimulation, have previously been suggested to have detri-
mental effects on embryo/blastocyst quality or chromosome
abnormalities on the basis of animal studies (25, 26).
However, in line with a previous study by Kok et al. (27),
the present study actually indicates that increasing
gonadotropin doses will not compromise the number of
good-quality oocytes that will develop to blastocysts. The
similar absolute numbers of blastocysts and good-quality
blastocysts obtained with low and high doses of gonadotro-
pins in the present study suggest that the larger oocyte
cohorts retrieved after stimulation with high doses are
composed of relatively few good-quality oocytes and many
additional oocytes that do not either fertilize or develop to
blastocysts. Furthermore, the inverse dose–response relation-
ship concerning fertilization rate may not only be attributed
to an increased proportion of nuclear immaturity (27) but
also tomore nuclear mature oocytes with compromised devel-
opment potential. The proportion of MII oocytes that develop
into blastocysts decreased with rhFSH dose. This was most
pronounced in the high AMH stratum; it is hypothesized
that moremetaphase II oocytes with poor development poten-
tial were recruited with increasing rhFSH doses in patients in
this stratum. These results would support the notion that only
a small number of the oocytes per retrieval have the potential
to develop into a competent embryo/blastocyst (28–32).
Finally, within each AMH stratum the increase in the
number of oocytes retrieved with increasing doses of rhFSH
was not associated with higher clinical pregnancy or live
birth rates in the fresh cycle or the cumulative fresh and
cryopreserved mandatory single blastocyst transfer cycles.
The numerically lower cumulative success rates in patients
in the low AMH stratum compared with patients in the high
AMH stratum seem to be a logical observation and are
thought to be dependent on a diminished ovarian reserve in
the patients with low AMH.
In conclusion, a signiﬁcant positive relationship between
the administered dose of rhFSH and the number of oocytes
retrieved was demonstrated, with different slopes of the
dose–response curves for women with low or high initial
AMH levels, respectively. The women in the high AMH
stratum had signiﬁcantly more blastocysts available for
transfer than women in the low AMH stratum, but in neither
stratum did the increased oocyte yield at higher gonadotropin
doses result in a similar increase in the numbers of blasto-
cysts. It is suggested that there may exist a threshold level
for the starting gonadotropin dose, related to the AMH level,
above which more intense stimulation has a limited effect on
increasing the number of competent oocytes. The data from
this prospective trial provide further arguments for elabo-
rating on more individualized gonadotropin-dosing regimens
that fulﬁll quantitative and qualitative ovarian response
objectives for IVF/ICSI.
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SUPPLEMENTAL FIGURE 1
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Assignment, treatment, and analysis of patients. ITT ¼ intention to treat.
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SUPPLEMENTAL FIGURE 2
Distribution of initial AMH levels in the whole trial population.
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SUPPLEMENTAL FIGURE 3
(A, B) Oocytes retrieved, metaphase II (MII) oocytes, and blastocysts by rhFSH dose group for the patients inseminated by ICSI (A, high AMH; B, low
AMH). (C,D) Mean rate of blastocysts to MII oocytes for the ICSI patients (C, high AMH;D, low AMH). The vertical bars represent standard errors. P
values reﬂect the dose–response relationship.
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SUPPLEMENTAL TABLE 1
Demographic and baseline characteristics of the patients, according to treatment group.
Characteristic
rhFSH
Follitropin alfa
11 mg (n[ 43) P valuea
5.2 mg
(n[ 42)
6.9 mg
(n[ 45)
8.6 mg
(n[ 44)
10.3 mg
(n[ 44)
12.1 mg
(n[ 47)
Age, y 33.6  2.2 32.3  3.5 32.8  2.4 32.3  3.2 32.6  3.0 32.4  3.0 .394
BMI, kg/m2 23.0  3.5 23.2  3.2 23.2  2.8 22.4  2.6 22.3  2.5 24.2  3.6 .050
Infertility history
Duration of infertility, y 3.3  2.0 3.1  2.2 3.4  2.3 3.3  2.3 3.4  2.4 2.8  1.4 .787
Primary infertility, n (%) 28 (67) 32 (71) 30 (68) 35 (80) 33 (70) 25 (58) .427
Reason of infertility, n (%) .915
Unexplained 24 (57) 21 (47) 23 (52) 23 (52) 23 (49) 20 (47)
Tubal 5 (12) 4 (9) 2 (5) 1 (2) 5 (11) 6 (14)
Mild male 6 (14) 7 (16) 10 (23) 6 (14) 9 (19) 9 (21)
Moderate/severe male 7 (17) 11 (24) 8 (18) 12 (27) 8 (17) 7 (16)
Endometriosis I/II 0 (0) 2 (4) 1 (2) 1 (2) 1 (2) 1 (2)
Other 0 (0) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0)
Endocrine proﬁle
AMHb
All patients
pmol/L 16 (9–23) 18 (9–27) 16 (10–22) 16 (11–25) 16 (10–29) 19 (10–28) .864
ng/mL 2.2 (1.3–3.2) 2.5 (1.3–3.8) 2.2 (1.4–3.1) 2.2 (1.5–3.5) 2.2 (1.4–4.1) 2.7 (1.4–3.9)
Low AMH stratumc
pmol/L 9 (7–11) 9 (7–12) 9 (7–11) 10 (8–13) 10 (7–11) 10 (9–12) .740
ng/mL 1.3 (1.0–1.5) 1.3 (1.0–1.7) 1.3 (1.0–1.5) 1.4 (1.1–1.8) 1.4 (1.0–1.5) 1.4 (1.3–1.7)
High AMH stratumd
pmol/L 23 (17–29) 26 (19–29) 22 (19–29) 25 (21–34) 26 (19–31) 26 (19–31) .684
ng/mL 3.2 (2.4–4.1) 3.6 (2.7–4.1) 3.1 (2.7–4.1) 3.5 (2.9–4.8) 3.6 (2.7–4.3) 3.6 (2.7–4.3)
FSH (IU/L)
All patients 6.4 (5.1–7.7) 7.0 (5.8–7.8) 6.6 (6.1–8.1) 6.9 (5.8–8.0) 7.0 (6.1–9.4) 6.8 (5.4–8.1) .317
Low AMH stratum 6.1 (5.7–7.8) 7.2 (5.4–8.2) 7.9 (6.6–9.3) 7.6 (6.5–8.5) 8.0 (6.2–10.1) 6.9 (6.2–8.1) .262
High AMH stratum 6.6 (4.9–7.3) 6.8 (5.8–7.3) 6.2 (5.3–6.7) 6.6 (5.3–7.6) 6.9 (6.1–8.1) 6.3 (5.1–8.1) .338
AFC, ne
All patients 13.7  4.4 13.2  4.7 13.5  4.4 14.5  4.4 14.3  4.5 14.0  4.2 .723
Low AMH stratum 11.6  3.7 11.5  2.9 11.6  3.6 12.0  3.2 13.3  4.8 12.1  2.7 .781
High AMH stratum 15.4  4.3 14.5  5.3 15.2  4.4 16.7  4.1 15.1  4.2 15.3  4.7 .686
Note: Plus-minus values are means  SD. Hormone values are median (interquartile range). BMI ¼ body mass index.
a P values are based on global tests to assess heterogeneity among treatment groups. P values for categorical variables are based on a two-sided c2 test. P values for continuous variables are based
on analysis of variance of the van der Waerden normal scores (mean values) or the Kruskal-Wallis test (median values).
b The serum concentration of AMH was assessed by a central laboratory using Beckman Coulter Gen 2 ELISA.
c The low AMH stratum is a serum AMH concentration in the range from 5.0 to 14.9 pmol/L (0.7 to <2.1 ng/mL).
d The high AMH stratum is a serum AMH concentration in the range from 15.0 to 44.9 pmol/L (2.1 to 6.3 ng/mL).
e This measurement reports the total number of antral follicles with a diameter from 2 to 10 mm for both ovaries combined, assessed by transvaginal ultrasound at the day of starting COS.
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SUPPLEMENTAL TABLE 2
Oocytes retrieved, metaphase II oocytes, and nonmature oocytes of the ICSI patients, according to treatment group.
Characteristic
rhFSH
Follitropin alfa 11 mg
(n[ 35) P valuea
5.2 mg
(n[ 33)
6.9 mg
(n[ 38)
8.6 mg
(n[ 35)
10.3 mg
(n[ 35)
12.1 mg
(n[ 31)
Oocytes retrieved
All patients 5.1  2.2 8.1  5.3 9.3  4.5 10.8  7.3 11.7  5.7 10.2  4.9 < .001
Low AMH stratumb 4.9  2.1 7.1  4.8 7.5  3.5 7.3  3.8 8.9  3.3 8.0  3.4 < .001
High AMH stratumc 5.4  2.4 8.9  5.6 11.2  4.7 14.1  8.3 14.7  6.2 12.0  5.2 < .001
MII oocytes
All patients 4.3  2.1 6.7  4.4 6.9  3.1 8.3  6.0 8.4  3.7 7.9  4.2 < .001
Low AMH stratum 4.3  1.9 5.8  4.3 5.7  2.5 6.1  3.0 6.9  2.6 6.2  3.0 .019
High AMH stratum 4.4  2.3 7.3  4.5 8.2  3.2 10.3  7.4 10.0  4.1 9.4  4.6 < .001
MI oocytes
All patients 0.3  0.5 0.6  1.0 0.7  0.8 0.9  1.3 1.0  1.2 1.1  1.3 < .001
Low AMH stratum 0.4  0.5 0.4  0.6 0.6  0.7 0.3  0.6 0.5  0.9 0.6  0.9 .830
High AMH stratum 0.2  0.4 0.6  1.1 0.8  0.8 1.4  1.5 1.5  1.3 1.5  1.4 < .001
Germinal vesicle oocytes
All patients 0.5  0.8 0.8  1.1 1.5  1.7 1.4  1.7 1.8  2.6 0.9  1.1 < .001
Low AMH stratum 0.2  0.4 0.9  1.2 1.2  1.7 0.8  1.2 1.4  2.1 1.0  1.2 .051
High AMH stratum 0.8  1.0 0.7  1.0 1.7  1.6 1.9  1.9 2.3  3.0 0.8  1.1 .001
Degenerated atretic oocytes
All patients 0.0  0.2 0.2  0.4 0.3  0.7 0.2  0.5 0.4  1.2 0.3  0.8 .020
Low AMH stratum 0.0  0.0 0.0  0.0 0.0  0.0 0.1  0.3 0.1  0.3 0.2  0.8 .060
High AMH stratum 0.1  0.2 0.3  0.6 0.6  0.9 0.3  0.6 0.8  1.7 0.4  0.8 .045
Note: Plus-minus values are means  SD.
a P values for dose–response based on F test from an analysis of covariance model.
b The low AMH stratum is a serum AMH concentration in the range from 5.0 to 14.9 pmol/L (0.7 to <2.1 ng/mL).
c The high AMH stratum is a serum AMH concentration in the range from 15.0 to 44.9 pmol/L (2.1 to 6.3 ng/mL).
Arce. AMH and ovarian response to rhFSH. Fertil Steril 2014.
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